Signal from the log
Consano Bio
15 M$ · United States
Consano Bio, près de Boston, développe C-1101, un mélange de protéines tirées des plaquettes injecté près des racines nerveuses pour réparer la cause de la sciatique chronique. Plus de 15 M$ levés auprès d'investisseurs privés, sans fonds nommé, pour finir l'essai de phase 1.
Spotted
Announced on , logged by the watch of 5 October 2026.
- Operation
- Funding round
- Announced amount
- 15 M$
- Country
- United States
What the log says
Editorial note, in French
Repérée par la collecte. Personne ne l'a encore instruite.
What is missing before publishing
- No fund is publicly named. It is the first condition of the selection bar: without a named investor there is no round to tell.
- The stage of the round is not disclosed. A letter is never inferred from an amount or a track record.
Provenance
Source prnewswire
Logged on 5 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Spotted The collection saw this operation and logged it. Nobody has processed it yet, so what is shown is still an automatic reading of the source headline.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.